The Role of Hypothalamic H3 Histamine Receptors in Regulation of Striatal Function

下丘脑 H3 组胺受体在纹状体功能调节中的作用

基本信息

  • 批准号:
    10534998
  • 负责人:
  • 金额:
    $ 6.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Allergic inflammation is associated with a number of neuropsychiatric disorders exhibiting striatal dysregulation, including autism, obsessive-compulsive disorder, and schizophrenia. However, the mechanisms underlying these links remain unknown. One possible influence on striatal function is the peripheral immune mediator histamine. Histamine is not only a key mediator of the allergic immune response, but is also a central neurotransmitter. Neurotransmitter histamine is produced solely by the posterior tuberomammillary nucleus (TMN) of the hypothalamus. Histaminergic neurons co-release GABA; they innervate the striatum, where they maintain tonic inhibition to suppress striatal hyperactivity. An observation in a genetic mouse line lacking histamine, the histidine decarboxylase (Hdc) knockout mouse, suggests a possible connection between systemic histamine and striatal activity. Hdc-KO mice exhibit upregulation of the histamine autoreceptor H3R, particularly in the TMN, and have greater baseline neuronal activity in the striatum. Systemic activation of the H3R receptor promotes further enhanced striatal activity. In wild-type mice, chemogenetic silencing of the TMN also enhanced striatal activity. The hypothalamus is surrounded by circumventricular organs which allow relatively free passage of systemic immune signals, such as histamine. We hypothesize that systemic histamine directly modulates TMN activity via H3R and thereby regulates downstream activity in the striatum. The first Aim tests whether H3R upregulation in the TMN in Hdc-KO mice mediates the effects of systemic administration of the H3R agonist RAMH on striatal activity. This will inform future work exploring the effects of histamine derived from mast cells and other allergic immune cells within the hypothalamus on TMN and striatal activity. Targeted delivery of RAMH to the TMN will test the sufficiency of TMN H3R activation to induce striatal hyperactivity, and shRNA-targeted downregulation of H3R in the TMN will test the necessity of these receptors in mediating striatal hyperactivity after systemic RAMH in both WT and Hdc-KO mice. The second Aim tests whether overexpression of H3R in the TMN is sufficient to recapitulate the striatal activity phenotype observed in Hdc-KO mice, which would further support the importance of hypothalamic H3R in modulating striatal activity phenotypes. Finally, in Aim 3, I test whether allergic inflammation affects neural activity in the TMH and the striatum, and whether this is mediated by hypothalamic H3R. This work will lay the groundwork for further investigations of immune control of the TMN and downstream brain targets, with potential relevance to a wide spectrum of neuropsychiatric disorders.
过敏性炎症与表现纹状体的许多神经精神疾病有关

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher Fields其他文献

Christopher Fields的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher Fields', 18)}}的其他基金

The Role of Hypothalamic H3 Histamine Receptors in Regulation of Striatal Function
下丘脑 H3 组胺受体在纹状体功能调节中的作用
  • 批准号:
    10685282
  • 财政年份:
    2022
  • 资助金额:
    $ 6.98万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 6.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 6.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 6.98万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 6.98万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 6.98万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 6.98万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 6.98万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 6.98万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 6.98万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 6.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了